ArticleFrontiers in immunology2026
Diagnostic delay in the early phase of psoriatic arthritis is independently associated with adverse pain-related cognitive responses: a multicentre cross-sectional study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Diagnostic delay during the early phase of psoriatic arthritis (PsA) is associated with worse long-term outcomes. Thus, early recognition remains crucial. Whether the delayed recognition of early PsA is associated with adverse pain-related cognitive responses has not been investigated. We examined the association between diagnostic delay, time to first biologic or targeted synthetic DMARD (b/tsDMARD) initiation, and pain-related cognitive burden in a multicentre cohort of patients with PsA. Methods: We conducted a multicentre cross-sectional study within three Italian referral centres for PsA. Adverse pain-related cognitive responses were investigated using the Pain Catastrophizing Scale (PCS), which captures the domains of rumination, magnification and helplessness. A total PCS score ≥ 30 was used as cut-off to define PCS-defined pain impairment. We defined: diagnostic delay as the lag time between symptoms onset and confirmed PsA diagnosis; therapeutic delay as the interval between PsA diagnosis and first b/tsDMARD initiation. Clinical, laboratory and patient-reported variables were compared according to PCS status. Multivariable logistic regression analysis was used to identify factors independently associated with pain catastrophizing. Results: Among 207 patients, 31.4% had PCS ≥30. Patients with PCS-defined impairment had significantly higher pain VAS, patient global assessment, evaluator global assessment, tender joint count, swollen joint count, ESR, DAPSA, BASDAI and ASDAS-CRP scores. Higher WPI, SSS and BDI scores were also reported amongst those with PCS ≥30. Diagnostic delay ≥6 months and therapeutic delay were observed to be more frequent in patients with PCS ≥30 (p=0.017 and p=0.045 respectively). Patients with delayed diagnosis had significantly higher PCS total score and within the subdomains of rumination, magnification and helplessness. The multivariable analysis showed the independent association of the diagnostic delay with PCS ≥30 (OR 3.65, 95% CI 1.21-11.02). Conclusion: Delayed recognition in the early phase of PsA is independently associated with adverse pain-related cognitive burden, as defined by the Pain Catastrophizing Scale.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.